Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study

Area of Science:

• Medical Oncology
• Pharmacology

Background:

• Advanced soft tissue sarcoma is a challenging diagnosis with limited treatment options.
• Chemotherapy remains a cornerstone in managing advanced soft tissue sarcoma.

Purpose of the Study:

• To compare the efficacy and toxicity of carminomycin (CMM) and adriamycin (ADM) in patients with advanced soft tissue sarcoma.
• To evaluate response rates, time to progression, and survival in patients treated with CMM versus ADM.

Main Methods:

• A randomized phase II study was conducted with 83 patients with advanced soft tissue sarcoma.
• Patients received either carminomycin (20 mg/m2) or adriamycin (75 mg/m2) intravenously every 3 weeks.
• Efficacy was assessed by response rate, duration of response, and time to progression; toxicity was also monitored.

Main Results:

• Adriamycin showed a significantly higher overall response rate (29%) compared to carminomycin (3%) (P=0.01).
• Median time to progression was significantly longer with ADM (5 months) than with CMM (2 months) (P=0.001).
• While survival was marginally longer with ADM (P=0.06), toxicities like nausea, vomiting, and alopecia were more severe in the ADM group.

Conclusions:

• Adriamycin is more effective than carminomycin for advanced soft tissue sarcoma.
• Both agents exhibit comparable leucopenia, but ADM is associated with more severe gastrointestinal and dermatological toxicities.
• Further investigation into optimal dosing and combination therapies may be warranted.